AZD 6422
Alternative Names: AZD-6422Latest Information Update: 08 Jan 2024
At a glance
- Originator AstraZeneca
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Gastrointestinal cancer
Most Recent Events
- 14 Dec 2023 Phase-I clinical trials in Gastrointestinal cancer (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in China (Parenteral) (NCT05981235)
- 08 Aug 2023 Peking University plans a phase I trial for Gastrointestinal cancer (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in China (Parenteral) in November 2023 (NCT05981235)
- 08 Aug 2023 Preclinical trials in Gastrointestinal cancer in United Kingdom (Parenteral) before August 2023